News

Rosen Law Firm Investigates Nike NFTs for Potential Claims

Rosen Law Firm Investigates Nike NFTs for Potential Claims

Rosen Law Firm Investigates Claims for Nike NFTs

The Rosen Law Firm has launched an investigation aimed at helping individuals who purchased Nike-themed non-fungible tokens (NFTs) issued by RTFKT, Inc. This inquiry is prompted by potential claims under state and federal laws concerning these crypto collectibles.

Understanding the Situation for NFT Purchasers

If you have made a purchase of Nike NFTs through RTFKT, this situation may entitle you to some form of compensation. The firm assures that no out-of-pocket costs will be necessary to pursue this claim, under a contingency fee setup. Currently, the Rosen Law Firm is preparing a class action lawsuit to assist investors in recovering their losses.

What to Do If You Are Affected

For those interested in joining this class action, reach out to the Rosen Law Firm without delay. They offer two straightforward options: either visit their secure online form to express your interest or connect with Phillip Kim, Esq., via their toll-free number for more direct guidance.

Background on RTFKT and Recent Developments

In a recent announcement via a social media platform, RTFKT disclosed plans to discontinue its operations. This news has raised concerns among NFT holders, particularly those who invested based on Nike's endorsement of these digital tokens. Investors now face uncertainties regarding the validity and future of their NFT holdings.

Choosing the Right Legal Representation

When selecting legal representation, it is vital for investors to choose firms with demonstrated success and credibility. The Rosen Law Firm has established a strong reputation in securities class actions and related litigation, having recovered significant amounts for investors in previous cases.

Rosen Law Firm's Proven Track Record

The firm has achieved notable milestones, including recovering over $438 million for investors in a single year. Notably, it was ranked first in terms of securities class action settlements a few years back, a testament to its capability and experience.

Commitment to Client Advocacy

Rosen Law Firm prides itself on being client-centered, representing individuals globally and focusing on advocacy in securities law. The leadership within the firm has garnered respect within the legal community, with several attorneys recognized for their expertise and contributions.

Stay Updated with Rosen Law Firm

For those affected and interested in staying informed, Rosen Law Firm encourages following their updates across popular social media platforms. This can be an excellent way to receive timely information regarding the class action's progress and other relevant developments.

Contact Information for Inquiries

If you wish to reach out to Rosen Law Firm directly, you can find their contact details below:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll-Free: (866) 767-3653
Fax: (212) 202-3827
Email: [email protected]
Website: www.rosenlegal.com

Frequently Asked Questions

What is the purpose of the investigation by Rosen Law Firm?

The investigation aims to identify potential claims for individuals who purchased Nike NFTs issued by RTFKT, assisting them in seeking compensation.

How can I join the class action?

Interested individuals can visit the Rosen Law Firm's website or contact Phillip Kim, Esq. directly for guidance on joining the class action.

What recent news triggered this investigation?

RTFKT's announcement regarding the winding down of its operations raised concerns about the value and future of the Nike NFTs.

What makes Rosen Law Firm a good choice for legal representation?

Rosen Law Firm boasts a substantial track record of successful settlements and a strong commitment to advocating for investor rights.

Where can I find updates about the class action?

The firm shares updates on various social media channels, including LinkedIn, Twitter, and Facebook, ensuring clients stay informed.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Innovent's Seven Drugs Leap onto 2026 Reimbursement Chart

Updated Category News Views 223

A Bold Move in Biopharmaceuticals Innovent Biologics just pulled a rabbit out of their hat. Seven of their cutting-edge meds made it onto China's National Reimbursement Drug List for 2026. This isn't just a spreadsheet entry—it's a lifeline thrown to patients across the oncology, metabolic, and autoimmune landscapes, as well as a financial booster for Innovent (HKEX:...

Continue Reading
CARsgen's CAR-T Breakthrough on China's Insurance List

Updated Category News Views 154

A Game Changer for CAR-T Therapies There's a breeze of optimism blowing from Shanghai these days—a rare sensation in this market of endless skirmishes. CARsgen Therapeutics Holdings Limited, a company entrenched in the development of cutting-edge CAR T-cell therapies, just notched a victory. They've announced that their CAR T-cell therapy product, satricabtagene...

Continue Reading
Fluence Energy Faces Leadership Departures Amid Legal Woes

Updated Category News Views 122

Fluence Energy's Rocky Road Continues It's chaos once again in the halls of Fluence Energy (NASDAQ:FLNC). The ship seems to drift further from solid ground as their CEO and CFO candidly decided to jump ship, shaking investor confidence even more vigorously. The market's reaction was swift and brutal: a nasty 9% share drop, leaving investors with more than just a headache....

Continue Reading
ManuTech Center Set to Revolutionize Manufacturing Hub

Updated Category News Views 207

Jackson's Next Manufacturing Frontier Well, the folks down in Jackson, Michigan, are prepping to cut the red ribbon on something that's got me leaning forward in my seat. The Advanced Manufacturing Training Center (AMTC) is pulling out all the stops with their new ManuTech Prototyping Center. Yup, this center is about to become the playground for startups, manufacturers,...

Continue Reading
Uber Data Breach: Class Action Investigation Begins

Updated Category News Views 22

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

Continue Reading
SmallRig Boosts Art-Driven Innovation in AI Era

Updated Category News Views 148

The Interplay of Art and AI In a world where the lines between man and machine blur faster than ever, creators like SmallRig are boldly asking: what role should authenticity play when AI takes the stage? The Shenzhen International Art Museum and SmallRig stood shoulder to shoulder, tackling this head-scrambling question with a global gathering of art and tech giants. It's...

Continue Reading
WeFetch AI: A New Era in Barcode Precision

Updated Category News Views 225

WeFetch AI: What's in a Name? Forget about GreenCore Solutions Corp. We're talking about WeFetch AI Corp. now. They've just changed their name, fulfilling a bureaucratic tick as of November 13, 2026. But it ain't just a name change; it's a whole new ballgame in AI-driven commerce. AI Shopping Without the Guesswork We've all been there. You think you've ordered that...

Continue Reading
Servier's Data on Tovorafenib Shows Promise in pLGG

Updated Category News Views 155

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

Continue Reading
EFICYENT Ventures to Connect at Singapore FinTech Fest

Updated Category News Views 150

Why the Singapore FinTech Festival Matters The world's hardly a stranger to hype, but the Singapore FinTech Festival carries some real weight. From November 18 to 20, 2026, this gig isn't just industry chatter—it's a high-stakes convergence of policymakers, financial institutions, fintech innovators like EFICYENT, and the money folk looking to mold the future of...

Continue Reading
Gaine Expands Healthcare Data Solutions Ahead of HLTH 2026

Updated Category News Views 233

Ever felt like healthcare systems are still stuck in a bygone era, struggling with data flinging through the void? Well, Gaine Technology is throwing down its gauntlet to change that narrative. Successful in pharmaceuticals and life sciences, they're turbocharging their Consent and Preference Management solution across the vast, tangled web of healthcare markets just in...

Continue Reading
les" class="btn" href="https://investorshangout.com/blog/news?page=2">More News Articles